Patient Perspectives in Mantle Cell Lymphoma Clinical Research
Study Details
Study Description
Brief Summary
Clinical studies with a distinct emphasis on mantle cell lymphoma play a pivotal role in evaluating the safety and effectiveness of novel treatments for this disease. These trials are instrumental in ascertaining whether new medications surpass conventional therapies, providing substantial evidence to endorse their broad utilization.
This particular study stands out as it centers on the firsthand experiences of individuals battling mantle cell lymphoma who are actively engaged in a clinical trial featuring medicinal interventions. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this patient group.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of patients who decide to enroll in a mantle cell lymphoma clinical study [3 months]
- Rate of patients who remain in a mantle cell lymphoma clinical study to trial completion [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Confirmed diagnosis of mantle cell lymphoma
-
No serious medical or psychiatric illness likely to interfere with participation in this clinical study.
-
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
-
Concurrent participation in another therapeutic clinical trial.
-
Subject has an uncontrolled infection
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Power Life Sciences | San Francisco | California | United States | 94107 |
Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Campbell J, Hurtado S, Kutz C, Soto K, Ernst D. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients]. Rev Med Chil. 2019;147(1):9-17. doi: 10.4067/S0034-98872019000100009. Spanish.
- Dasappa L, Suresh Babu MC, Sirsath NT, Suresh TM, Govind Babu K, Sathyanarayna V, Lokesh KN, Lakshmaiah KC. Primary gastrointestinal mantle cell lymphoma: a retrospective study. J Gastrointest Cancer. 2014 Dec;45(4):481-6. doi: 10.1007/s12029-014-9655-2.
- Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22. doi: 10.1002/cncr.22093.
- 70247036